Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Name: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Published: 2021
License: Public Domain

AbbVie · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

hepatitis-c

hepatitis c virus (hcv), acute hcv infection, hcv genotype 1-6, hepatitis c, glecaprevir, pibrentasvir, mavyret, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Related documents